Hotspot in the genome may drive psychosis in schizophrenia and bipolar disorder

Hotspot in the genome may drive psychosis in schizophrenia and bipolar disorder
Dr. Viviane Labrie Credit: Van Andel Research Institute

A newly identified epigenetic hotspot for schizophrenia and bipolar disorder may give scientists a fresh path forward for devising more effective treatments and biomarker-based screening strategies.

More than 100 million people worldwide have either schizophrenia or , which are characterized by periods of hallucinations, delusions and irregular thought processes. They are both associated with overproduction of the neurotransmitter , a key regulator of reward-seeking behavior, , learning and movement, among other functions.

While effective medications do exist, they often have challenging side effects such as apathy, and uncontrolled movements called dyskinesias that typically are associated with Parkinson's disease. Currently, there are no effective biomarkers for screening and tracking progression of either disorder.

"We've known since the 1970s that the effectiveness of antipsychotic medications is directly related to their ability to block dopamine signaling. However, the exact mechanism that sparks excessive dopamine in the brain and that leads to has been unclear," said Viviane Labrie, Ph.D., assistant professor at Van Andel Research Institute (VARI) and corresponding author of the study, which appears in the May 3 edition of Nature Communications. "We now have a biological explanation that could help make a real difference for people with these ."

Labrie and her collaborators found a cluster of epigenetic marks that ratchets up dopamine production while simultaneously scrambling the brain's synapses, the information hubs that transmit rapid-fire neural messages responsible for healthy function. The result is a catastrophic shake-up of the brain's organization and chemical balance that fuels symptoms of psychosis.

Dr. Viviane Labrie of Van Andel Research Institute discusses how an epigenetic hotspot may contribute to symptoms of schizophrenia and bipolar disorder. Credit: Van Andel Research Institute

"What we're seeing is a one-two punch—the brain is being flooded with too much dopamine and at the same time it is losing these critical neural connections," Labrie said. "Like many other neurological disorders, schizophrenia and bipolar disorder often have early, or prodromal, phases that begin years before obvious symptoms. It is our hope that our findings may lead to new biomarkers to screen for risk, which would then allow for earlier intervention."

The team took a comprehensive, broad look at DNA derived from brain cells of people with either schizophrenia or bipolar disorder and compared them to healthy controls. Their analyses revealed a cluster of epigenetic marks, which switch genes on and off, in an enhancer at a gene called IGF2, a critical regulator of synaptic development. Enhancers are stretches of DNA that help activate genes and can be major players in the development of diseases in the brain and other tissues.

This enhancer also controls the activity of a nearby gene called tyrosine hydroxylase, which produces an enzyme that keeps dopamine in check. When the enhancer is epigenetically switched on, production of dopamine becomes dysregulated, resulting in too much of the chemical in the brain.

Taken together, molecular changes at this site may explain why psychosis brought on by dopamine frequently is accompanied by a disruption of brain synapses, a devastating double-hit that promotes symptoms.

The study controlled for , sex, ethnicity, treatment history and lifestyle influences such as smoking, and the results were validated in experimental models of the disease.

"We used cutting-edge computational strategies to understand the events occurring in cells that underlie psychiatric disorders," said Shraddha Pai, Ph.D., a postdoctoral fellow at University of Toronto and the study's first author. "Our results were strengthened by additional studies in disease models. This comprehensive approach lends weight to our findings, which we believe will propel additional groundbreaking investigations into this enhancer at the IGF2 gene."

More information: Shraddha Pai et al, Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis, Nature Communications (2019). DOI: 10.1038/s41467-019-09786-7

Journal information: Nature Communications

Citation: Hotspot in the genome may drive psychosis in schizophrenia and bipolar disorder (2019, May 3) retrieved 1 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

A new model to trial preventative treatments for schizophrenia


Feedback to editors